<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>neuroinflammation and epilepsy progression &#8211; Science</title>
	<atom:link href="https://scienmag.com/tag/neuroinflammation-and-epilepsy-progression/feed/" rel="self" type="application/rss+xml" />
	<link>https://scienmag.com</link>
	<description></description>
	<lastBuildDate>Wed, 29 Jul 2026 18:23:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1</generator>

<image>
	<url>https://scienmag.com/wp-content/uploads/2024/07/cropped-scienmag_ico-32x32.jpg</url>
	<title>neuroinflammation and epilepsy progression &#8211; Science</title>
	<link>https://scienmag.com</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">73899611</site>	<item>
		<title>cGAS-mediated type I IFN signaling contributes to disease progression in drug-refractory epilepsy</title>
		<link>https://scienmag.com/cgas-mediated-type-i-ifn-signaling-contributes-to-disease-progression-in-drug-refractory-epilepsy/</link>
		
		<dc:creator><![CDATA[Kendall Mcintyre]]></dc:creator>
		<pubDate>Wed, 29 Jul 2026 18:23:06 +0000</pubDate>
				<category><![CDATA[Medicine]]></category>
		<category><![CDATA[cGAS-mediated immune response in epilepsy]]></category>
		<category><![CDATA[disease progression in refractory epilepsy]]></category>
		<category><![CDATA[immune-mediated neurodegeneration]]></category>
		<category><![CDATA[innate immune pathways in neurological disorders]]></category>
		<category><![CDATA[innate immunity and seizure disorders]]></category>
		<category><![CDATA[molecular mechanisms of drug-refractory epilepsy]]></category>
		<category><![CDATA[neuroimmune interactions in epilepsy]]></category>
		<category><![CDATA[neuroinflammation and epilepsy progression]]></category>
		<category><![CDATA[neuroinflammatory signaling pathways]]></category>
		<category><![CDATA[role of cGAS-STING pathway in epilepsy]]></category>
		<category><![CDATA[therapeutic targets for drug-resistant epilepsy]]></category>
		<category><![CDATA[type I interferon signaling in drug-resistant epilepsy]]></category>
		<guid isPermaLink="false">https://scienmag.com/cgas-mediated-type-i-ifn-signaling-contributes-to-disease-progression-in-drug-refractory-epilepsy/</guid>

					<description><![CDATA[Huang, Y., Fan, L., Wong, M.Y. et al. cGAS-mediated type I IFN signaling contributes to disease progression in drug-refractory epilepsy. Nat Neurosci (2026). https://doi.org/10.1038/s41593-026-02384-z https://doi.org/10.1038/s41593-026-02384-z]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" src="https://media.springernature.com/w290h158/springer-static/image/art%3A10.1038/s41593-026-02384-z/MediaObjects/41593_2026_2384_Fig1_HTML.png" /></p>
<p class="c-bibliographic-information__citation">Huang, Y., Fan, L., Wong, M.Y. <i>et al.</i> cGAS-mediated type I IFN signaling contributes to disease progression in drug-refractory epilepsy.<br />
                    <i>Nat Neurosci</i>  (2026). https://doi.org/10.1038/s41593-026-02384-z</p>
<p><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41593-026-02384-z</span></p>
]]></content:encoded>
					
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">175472</post-id>	</item>
	</channel>
</rss>
